Table 1.
Baseline demographic and disease characteristics of patients
| Variable | Overall (N = 222) | Treatment group | |
|---|---|---|---|
| 2 years (N = 112) n (%) | 3 or more years (N = 110) n (%) | ||
| Age (years) | |||
| Median (range) | 43.0 (25–56) | 43.5 (25–52) | 43.0 (27–56) |
| BMI (kg/m2) | |||
| Mean (SD) | 21.8 (3.44) | 21.8 (3.29) | 21.8 (3.59) |
| Tumor stage (TNM classification) | |||
| I | 146 (65.8) | 74 (66.1) | 72 (65.5) |
| IIA | 60 (27.0) | 29 (25.9) | 31 (28.2) |
| IIB–IIIB | 16 (7.2) | 9 (8.0) | 7 (6.4) |
| Tumor size (cm) | |||
| ≤ 2 | 165 (74.3) | 84 (75.0) | 81 (73.6) |
| > 2 | 57 (25.7) | 28 (25.0) | 29 (26.4) |
| Number of axillary lymph nodes | |||
| 0 | 198 (89.2) | 100 (89.3) | 98 (89.1) |
| 1–max | 24 (10.8) | 12 (10.7) | 12 (10.9) |
| ER/PgR status | |||
| ER+/PgR+ | 207 (93.2) | 103 (92.0) | 104 (94.5) |
| ER+/PgR− | 9 (4.1) | 5 (4.5) | 4 (3.6) |
| ER−/PgR+ | 6 (2.7) | 4 (3.6) | 2 (1.8) |
| Preoperative chemotherapy | |||
| Presence | 4 (1.8) | 2 (1.8) | 2 (1.8) |
| Absence | 218 (98.2) | 110 (98.2) | 108 (98.2) |
| Postoperative chemotherapy | |||
| Presence | 23 (10.4) | 12 (10.7) | 11 (10.0) |
| Absence | 199 (89.6) | 100 (89.3) | 99 (90.0) |
| Serum E2 (pg/mL) at week 0 | |||
| Median (interquartile range) | 90.5 (50.0–170.0) | 88.0 (37.0–144.0) | 101.5 (59.0–204.0) |
Values represent the number (%) of patients unless otherwise indicated
BMI body mass index, ER estrogen receptor, PgR progesterone receptor, E 2 estradiol